keyword
https://read.qxmd.com/read/38647528/a-bispecific-antibody-that-targets-the-membrane-proximal-region-of-mesothelin-and-retains-high-anticancer-activity-in-the-presence-of-shed-mesothelin
#21
JOURNAL ARTICLE
Anirban Chakraborty, Masanori Onda, Tara O'Shea, Junxia Wei, Xiufen Liu, Tapan K Bera, Ira Pastan
Mesothelin (MSLN) is a cell-surface protein that is expressed on many cancers, which makes it a popular target for antibody-based cancer therapy. However, MSLN is shed from cancer cells at high levels via proteases that cleave at its membrane-proximal C-terminal region. Shed MSLN accumulates in patient fluids and tumors and can block antibody-based MSLN-targeting drugs from killing cancer cells. A previously established monoclonal antibody (mAb), 15B6, binds MSLN at its protease-sensitive C-terminal region and does not bind shed MSLN...
April 22, 2024: Molecular Cancer Therapeutics
https://read.qxmd.com/read/38646700/network-meta-analysis-of-car-t-cell-therapy-for-the-treatment-of-3l-r-r-lbcl-after-using-published-comparative-studies
#22
REVIEW
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
INTRODUCTION: Studies have compared chimeric antigen receptor (CAR) T-cell therapies and salvage chemotherapy in relapsed/refractory large B-cell lymphoma (LBCL) patients, but further evidence of their relative effectiveness is warranted. METHODS: Our systematic review identified studies comparing efficacy and safety outcomes of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) trials to salvage chemotherapy cohorts in LBCL patients with ≥ 2 prior lines of treatment; and an extended evidence network included indirect comparisons comparing CAR T-cell therapies...
April 22, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38646426/targeting-estrogen-mediated-cyp4f2-cyp4f11-20-hete-metabolic-disorder-decelerates-tumorigenesis-in-er-breast-cancer
#23
JOURNAL ARTICLE
Juan Yang, Yin Li, Xiao Han, Tianjiao Li, Ding Li, Qiao Liu, Lizhong Yan, Fei Li, Xiaolin Pei, Ya Feng, Zhoujun Lin, Zhenkun Fu, Changjun Wang, Qiang Sun, Chenggang Li
PURPOSE: As the most common subset of breast cancer (BC), estrogen receptor positive (ER+) BC accounting for 80% of cases, has become a global public health concern. The female hormone estrogen (E2) unequivocally drives ER + breast malignancies. The reasons that estrogen affects BC development has long been considered, yet further study remains to be conducted of the molecular events in the E2-estrogen receptor α (ERα) signaling pathway in ER + BC progression, especially lipid metabolism, so providing more options for tailored and individualized therapy...
July 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/38645875/emerging-insights-into-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-induced-by-immune-checkpoint-inhibitor-and-tumor-targeted-therapy
#24
JOURNAL ARTICLE
Min Lin, Ting Gong, Shifan Ruan, Xiaoqing Lv, Rongying Chen, Xinhong Su, Bo Cheng, Chao Ji
OBJECTIVE: Anticancer drugs have revolutionized tumor therapy, with cutaneous toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) being common immune-related adverse events. The debate over the efficacy of systemic corticosteroids in treating these conditions persists, while tumor necrosis factor (TNF)-alpha inhibitors show promise. This study aims to evaluate the effectiveness and safety of combination therapy involving the TNF-α inhibitor adalimumab for SJS/TEN induced by anticancer drugs...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38645563/chemotherapeutic-potential-of-betanin-capecitabine-combination-targeting-colon-cancer-experimental-and-bioinformatic-studies-exploring-nf%C3%AE%C2%BAb-and-cyclin-d1-interplay
#25
JOURNAL ARTICLE
Rehab Ahmed, Sawsan A Zaitone, Asmaa K K Abdelmaogood, Huda M Atef, Mona F M Soliman, Alaa M Badawy, Howaida S Ali, AbdelNaser Zaid, Hatem I Mokhtar, Lamiaa M Elabbasy, Emad Kandil, Asmaa Mokhtar Yosef, Rama I Mahran
Introduction: Betanin (C₂₄H₂₆N₂O₁₃) is safe to use as food additives approved by the FDA with anti-inflammatory and anticancer effects in many types of cancer cell lines. The current experiment was designed to test the chemotherapeutic effect of the combination of betanin with the standard chemotherapeutic agent, capecitabine, against chemically induced colon cancer in mice. Methods: Bioinformatic approach was designed to get information about the possible mechanisms through which the drugs may control cancer development...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38645331/new-salicylanilide-derivatives-and-their-peptide-conjugates-as-anticancer-compounds-synthesis-characterization-and-in-vitro-effect-on-glioblastoma
#26
JOURNAL ARTICLE
Lilla Horváth, Beáta Biri-Kovács, Zsuzsa Baranyai, Bence Stipsicz, Előd Méhes, Bálint Jezsó, Martin Krátký, Jarmila Vinšová, Szilvia Bősze
Pharmacologically active salicylanilides (2-hydroxy- N -phenylbenzamides) have been a promising area of interest in medicinal chemistry-related research for quite some time. This group of compounds has shown a wide spectrum of biological activities, including but not limited to anticancer effects. In this study, substituted salicylanilides were chosen to evaluate the in vitro activity on U87 human glioblastoma (GBM) cells. The parent salicylanilide, salicylanilide 5-chloropyrazinoates, a 4-aminosalicylic acid derivative, and the new salicylanilide 4-formylbenzoates were chemically and in vitro characterized...
April 16, 2024: ACS Omega
https://read.qxmd.com/read/38645328/design-synthesis-and-in-silico-and-in-vitro-cytotoxic-activities-of-novel-isoniazid-hydrazone-analogues-linked-to-fluorinated-sulfonate-esters
#27
JOURNAL ARTICLE
Eyüp Başaran, Gulal Tür, Senem Akkoc, Tugba Taskin-Tok
Cancer is a life-threatening disease, and significant efforts are still being made to treat it. In this study, we synthesized and characterized novel hybrid molecules ( 10 - 18 ) containing hydrazone and sulfonate moieties and tested their cell growth inhibitory effect on human colon cancer cells (DLD-1), human prostate cancer cells (PC3), and human embryonic kidney cells (HEK-293T) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method for 72 h. In cell culture studies, all tested hybrid molecules except for 12 and 13 showed significant cytotoxic activities at a micromolar level with IC50 values in the range of 10...
April 16, 2024: ACS Omega
https://read.qxmd.com/read/38645004/drug-loaded-nanoparticles-for-cancer-therapy-a-high-throughput-multicellular-agent-based-modeling-study
#28
Yafei Wang, Elmar Bucher, Heber Rocha, Vikram Jadhao, John Metzcar, Randy Heiland, Hermann B Frieboes, Paul Macklin
Interactions between biological systems and nanomaterials have become an important area of study due to the application of nanomaterials in medicine. In particular, the application of nanomaterials for cancer diagnosis or treatment presents a challenging opportunity due to the complex biology of this disease spanning multiple time and spatial scales. A system-level analysis would benefit from mathematical modeling and computational simulation to explore the interactions between anticancer drug-loaded nanoparticles (NPs), cells, and tissues, and the associated parameters driving this system and a patient's overall response...
April 12, 2024: bioRxiv
https://read.qxmd.com/read/38644824/anticancer-potential-of-grifolin-in-lung-cancer-treatment-through-pi3k-akt-pathway-inhibition
#29
JOURNAL ARTICLE
Li Wang, Yongjun Wang, Zexu Wang, Xiuwei Zhang, Huayong Chen, Qiuqi Lin, Xin Wang, Yuting Wen, Xia Pan, Zhongliang Guo, Bing Wan
OBJECTIVE: Grifolin is a natural secondary metabolite isolated from edible fruiting bodies of the mushroom Albatrellus confluens . Grifolin has antitumor activities in several types of cancer. We aimed to determine the effects of grifolin on lung cancer. METHODS: We determined the proliferation, migration, invasion, and apoptosis of lung cancer cells using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Ethynyl deoxyuridine, colony formation, wound scratch, transwell, flow cytometry, and xenograft mouse assays...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38644714/novel-piperazine-derivatives-as-potent-antihistamine-anti-inflammatory-and-anticancer-agents-their-synthesis-and-characterization
#30
JOURNAL ARTICLE
Ameer Mohammed R, Kannika K Shetty, Lairikyengbam Deepti Roy, Jyotsna Kumar
INTRODUCTION: In this study, a series of novel piperazine derivatives were synthesised with high-to-good yields, and their structural analogies were confirmed using FTIR, 1H-NMR, and LC-MS techniques. METHOD: The synthesised compounds were evaluated for antioxidant and antimicrobial activities. Among the four synthesised piperazine derivatives, compound PD-2 exhibited relatively good antioxidant activity, with an IC50 value of 2.396 μg/mL, while the other three derivatives showed moderate to low antioxidant activity...
April 18, 2024: Anti-cancer Agents in Medicinal Chemistry
https://read.qxmd.com/read/38644483/analyzing-genetic-diversity-in-luffa-and-developing-a-fusarium-wilt-susceptible-linked-snp-marker-through-a-single-plant-genome-wide-association-sp-gwas-study
#31
JOURNAL ARTICLE
Yun-Da Li, Yu-Chi Liu, Yu-Xuan Jiang, Ahmed Namisy, Wen-Hsin Chung, Ying-Hsuan Sun, Shu-Yun Chen
BACKGROUND: Luffa (Luffa spp.) is an economically important crop of the Cucurbitaceae family, commonly known as sponge gourd or vegetable gourd. It is an annual cross-pollinated crop primarily found in the subtropical and tropical regions of Asia, Australia, Africa, and the Americas. Luffa serves not only as a vegetable but also exhibits medicinal properties, including anti-inflammatory, antidiabetic, and anticancer effects. Moreover, the fiber derived from luffa finds extensive applications in various fields such as biotechnology and construction...
April 22, 2024: BMC Plant Biology
https://read.qxmd.com/read/38643825/olesoxime-protects-against-cisplatin-induced-acute-kidney-injury-by-attenuating-mitochondrial-dysfunction
#32
JOURNAL ARTICLE
Peipei Wang, Jing Ouyang, Kaiqian Zhou, Dandan Hu, Shengnan Zhang, Aihua Zhang, Yunwen Yang
BACKGROUND: Mitochondrial dysfunction is a critical factor in the pathogenesis of acute kidney injury (AKI). Agents that ameliorate mitochondrial dysfunction hold potential for AKI treatment. The objective of this study was to investigate the impact of olesoxime, a novel mitochondrial-targeted agent, on cisplatin-induced AKI. METHODS: In vivo, a cisplatin-induced AKI mouse model was established by administering a single intraperitoneal dose of cisplatin (25 mg/kg) to male C57BL/6 mice for 72 hours, followed by gavage of either olesoxime or a control solution...
April 19, 2024: Biomedical Journal
https://read.qxmd.com/read/38643705/microbial-exopolysaccharides-unveiling-the-pharmacological-aspects-for-therapeutic-advancements
#33
JOURNAL ARTICLE
Nahid Akhtar, Atif Khurshid Wani, Neeta Raj Sharma, Samira Sanami, Shaikh Kaleem, Moch Machfud, Titiek Purbiati, Sugiono Sugiono, Djumali Djumali, Paulina Evy Retnaning Prahardini, Rully Dyah Purwati, Khojin Supriadi, Farida Rahayu
Microbial exopolysaccharides (EPSs) have emerged as a fascinating area of research in the field of pharmacology due to their diverse and potent biological activities. This review paper aims to provide a comprehensive overview of the pharmacological properties exhibited by EPSs, shedding light on their potential applications in various therapeutic areas. The review begins by introducing EPSs, exploring their various sources, significance in microbial growth and survival, and their applications across different industries...
April 17, 2024: Carbohydrate Research
https://read.qxmd.com/read/38643157/trametinib-sensitizes-kras-mutant-lung-adenocarcinoma-tumors-to-pd-1-pd-l1-axis-blockade-via-id1-downregulation
#34
JOURNAL ARTICLE
Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo
BACKGROUND: The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on Id1 protein, a key factor involved in the KRAS oncogenic pathway, and investigates the role of Id1 in the acquired resistance to trametinib as well as the synergistic anticancer effect of trametinib combined with immunotherapy in KRAS-mutant LUAD. METHODS: We evaluated the effects of trametinib on KRAS-mutant LUAD by Western blot, RNA-seq and different syngeneic mouse models...
April 20, 2024: Molecular Cancer
https://read.qxmd.com/read/38643011/protocol-for-the-development-of-a-core-outcome-set-and-reporting-guidelines-for-locoregional-treatment-in-neoadjuvant-systemic-breast-cancer-treatment-trials-the-precedent-project
#35
JOURNAL ARTICLE
Shelley Potter, Kerry Avery, Rosina Ahmed, Jana de Boniface, Sanjoy Chatterjee, David Dodwell, Peter Dubsky, Hiroji Iwata, Michael Jiang, Han-Byoel Lee, Mairead MacKenzie, Fiorita Poulakaki, Andrea L Richardson, Karla Sepulveda, Andrew Spillane, Alastair M Thompson, Gustavo Werutsky, Jean L Wright, Nicholas Zdenkowski, Katherine Cowan, Stuart McIntosh
INTRODUCTION: Neoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to therapy is prognostic and allows locoregional and adjuvant systemic treatments to be tailored to minimise morbidity and optimise oncological outcomes and quality of life. Accurate information about locoregional treatments following neoSACT is vital to allow the translation of downstaging benefits into practice and facilitate meaningful interpretation of oncological outcomes, particularly locoregional recurrence...
April 19, 2024: BMJ Open
https://read.qxmd.com/read/38642809/synergistic-anticancer-effects-of-ginsenoside-ck-and-gefitinib-against-gefitinib-resistant-nsclc-by-regulating-the-balance-of-angiogenic-factors-through-hif-1%C3%AE-vegf
#36
JOURNAL ARTICLE
Xiaoping Song, Lina Wang, Panpan Cai, Ying Xu, Qingchao Liu, Daidi Fan
Drug resistance is a serious problem for gefitinib in the treatment of lung cancer. Ginsenoside CK, a metabolite of diol ginsenosides, have many excellent pharmacological activities, but whether ginsenoside CK can overcome gefitinib resistance remains unclear. In our study, the sensitizing activity of ginsenoside CK on gefitinib-resistant non-small cell lung cancer (NSCLC) in vitro and in vivo was investigated. Ginsenoside CK was confirmed to enhance the anti-proliferation, pro-apoptotic and anti-migration effects of gefitinib in primary and acquired resistant NSCLC...
April 18, 2024: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/38642515/synergistic-effects-of-photodynamic-therapy-and-chemotherapy-activating-the-intrinsic-extrinsic-apoptotic-pathway-of-anoikis-for-triple-negative-breast-cancer-treatment
#37
JOURNAL ARTICLE
Tianyu Zhang, Xueyuan Wang, Dongna Wang, Meng Lei, Yixue Hu, Zhimeng Chen, Yuting Li, Yingnan Luo, Liefeng Zhang, Yongqiang Zhu
Triple-negative breast cancer (TNBC) is a highly invasive and metastatic subtype of breast cancer that often recurs after surgery. Herein, we developed a cyclodextrin-based tumor-targeted nano delivery system that incorporated the photosensitizer chlorin e6 (Ce6) and the chemotherapeutic agent lonidamine (LND) to form the R6RGD-CMβCD-se-se-Ce6/LND nanoparticles (RCC/LND NPS). This nanosystem could target cancer cells, avoid lysosomal degradation and further localize within the mitochondria. The RCC/LND NPS had pH and redox-responsive to control the release of Ce6 and LND...
April 17, 2024: Biomater Adv
https://read.qxmd.com/read/38642330/one-stone-several-birds-self-localizing-submicrocages-with-dual-loading-points-for-multifunctional-drug-delivery
#38
JOURNAL ARTICLE
Shuxuan Liu, Jifei Wang, Yong Jiang, Yao Wang, Bin Yang, Hao Li, Guofu Zhou
As the core index, how to improve bioavailability of loaded cargoes has been a hot topic of drug carriers. In our study, aminated β-cyclodextrin (β-CD) as cross-linking points was first integrated into three-dimensional poly(acrylamide-co-acrylonitrile) network to build up a unique submicrocage (466.2± 47.6 nm), featuring upper critical solution temperature (UCST; ∼40 °C), high volume expansion coefficient and excellent biocompatibility. Hereinto hydrophobic β-elemene was locally loaded in β-CD with high loading efficiency (8...
April 20, 2024: Macromolecular Bioscience
https://read.qxmd.com/read/38642219/what-facets-of-physical-function-are-most-important-to-adults-diagnosed-with-cancer
#39
JOURNAL ARTICLE
Theresa Coles, Kate Plyler, Alexy Hernandez, Rebecca Fillipo, Debra M Henke, Cara Arizmendi, Sandhya Lagoo-Deenadayalan, C Rory Goodwin, Thomas W LeBlanc, Erica G Horodniceanu, Vishal Bhatnagar, Bryce B Reeve, Kevin P Weinfurt
PURPOSE: Successful patient-focused drug development involves selecting and measuring outcomes in clinical trials that are important to patients. The U.S. Food & Drug Administration's definition of clinical benefit includes how patients feel, function, or survive. Patients are considered the experts in describing how they feel and function. In cancer trials, patient-reported measures of physical function provide insight into how patients function at baseline, benefit from the interventions being studied, and the impact of treatment side effects...
April 20, 2024: Quality of Life Research
https://read.qxmd.com/read/38641308/celecoxib-and-sulindac-sulfide-elicit-anticancer-effects-on-pik3ca-mutated-head-and-neck-cancer-cells-through-endoplasmic-reticulum-stress-reactive-oxygen-species-and-mitochondrial-dysfunction
#40
JOURNAL ARTICLE
Nga Thi Thanh Nguyen, Sang Yoon Lee
Gain-of-function mutation in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha gene (PIK3CA) is a significant factor in head and neck cancer (HNC). Patients with HNC harboring PIK3CA mutations receive therapeutic benefits from the use of non-steroidal anti-inflammatory drugs (NSAIDs). However, the molecular mechanisms underlying these effects remain unknown. Here, we examined the Detroit562 and FaDu cell lines as HNC models with and without a hyperactive PIK3CA mutation (H1047R), respectively, regarding their possible distinct responses to the NSAIDs celecoxib and sulindac sulfide (SUS)...
April 17, 2024: Biochemical Pharmacology
keyword
keyword
159840
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.